Rosetta Genomics Ltd., Rehovot, Israel.
Mol Oncol. 2013 Jun;7(3):732-8. doi: 10.1016/j.molonc.2013.03.002. Epub 2013 Mar 26.
Renal cancers account for more than 3% of adult malignancies and cause more than 13,000 deaths per year in the US alone. The four most common types of kidney tumors include the malignant renal cell carcinomas; clear cell, papillary, chromophobe and the benign oncocytoma. These histological subtypes vary in their clinical course and prognosis, and different clinical strategies have been developed for their management. In some kidney tumor cases it can be very difficult for the pathologist to distinguish between tumor types on the basis of morphology and immunohistochemistry (IHC). In this publication we present the development and validation of a microRNA-based assay for classifying primary kidney tumors. The assay, which classifies the four main kidney tumor types, was developed based on the expression of a set of 24 microRNAs. A validation set of 201 independent samples was classified using the assay and analyzed blindly. The assay produced results for 92% of the samples with an accuracy of 95%.
肾细胞癌占成人恶性肿瘤的 3%以上,仅在美国每年就导致超过 13000 人死亡。四种最常见的肾肿瘤类型包括恶性肾细胞癌、透明细胞癌、乳头状癌、嫌色细胞癌和良性嗜酸细胞瘤。这些组织学亚型在临床过程和预后上有所不同,因此针对它们的管理制定了不同的临床策略。在某些肾肿瘤病例中,病理学家仅基于形态学和免疫组织化学(IHC)很难区分肿瘤类型。在本出版物中,我们介绍了一种基于 microRNA 的检测方法的开发和验证,用于对原发性肾肿瘤进行分类。该检测方法基于一组 24 个 microRNAs 的表达,可对四种主要的肾肿瘤类型进行分类。使用该检测方法对 201 个独立样本的验证集进行分类,并进行盲法分析。该检测方法对 92%的样本进行了分类,准确率为 95%。